Peptide Association
List Your Practice
Daily Peptide News

Latest Peptide News & Research

Breaking research, regulatory updates, and industry developments in the world of peptide science. Updated daily.

Updated yesterday at 6:01 AM UTC

ResearchHigh

Study Compares GLP-1 Drugs on Their Benefits, Harms

A comprehensive systematic review and network meta-analysis of 262 randomized studies evaluated the comparative benefits and harms of GLP-1 receptor agonist drugs, revealing variable outcomes in weight loss and cardiovascular endpoints across the drug class. The findings highlight meaningful differences between individual agents in terms of efficacy and safety profiles, offering clinicians a more nuanced framework for prescribing decisions. Effects on patient quality of life remained less conclusive, pointing to a critical gap in the existing evidence base for this rapidly growing therapeutic category.

GLP-1SemaglutideTirzepatideLiraglutide
MedPage TodayJuly 10, 2026
5 min read
ResearchHigh

Newer Diabetes Drugs, Including GLP-1 Agonists, Tied to Autoimmunity Risk

A large-scale analysis of hundreds of thousands of patient records has identified differing risks for new-onset autoimmune conditions among users of newer antidiabetic medications, including GLP-1 receptor agonists. The findings add an important safety dimension to the growing body of research surrounding GLP-1 based therapies, which have seen rapid adoption for both diabetes management and weight loss. Clinicians and researchers are now calling for closer monitoring of autoimmune markers in patients initiating these drug classes.

GLP-1
MedPage TodayJuly 9, 2026
5 min read
ResearchHigh

GLP-1s and Liver Cancer Recurrence; IBS Acupuncture; Transmural Healing in Crohn's

A target trial emulation study published in Gut found that diabetic patients with hepatocellular carcinoma who initiated a GLP-1 receptor agonist experienced significantly longer time to cancer recurrence and improved overall survival compared to those on DPP-4 inhibitors. The findings add to a growing body of evidence suggesting GLP-1 receptor agonists may confer oncologic benefits beyond glycemic control. This research strengthens the case for broader investigation of GLP-1 therapies in metabolic and hepatic disease management.

GLP-1
MedPage TodayJuly 9, 2026
5 min read
RegulatoryHigh

STAT+: Europe will accelerate its review of RevMed's drug

A broader biotech news roundup includes a notable reference to concerns raised over Kailera's GLP-1 pill trial data, adding complexity to the competitive oral GLP-1 receptor agonist space as multiple candidates vie for regulatory approval. The European Medicines Agency's decision to accelerate review of another drug compound further reflects heightened regulatory engagement across novel therapeutic modalities. These developments collectively illustrate the fast-moving regulatory and clinical environment surrounding next-generation GLP-1 therapies.

GLP-1
STAT NewsJuly 8, 2026
4 min read
Clinical TrialsCritical

New weight loss pill beats oral Ozempic in major trial

A major clinical trial has demonstrated that orforglipron, a once-daily oral small molecule weight loss pill, outperformed oral semaglutide in both weight reduction and blood sugar control, representing a potentially significant shift in the GLP-1 therapeutic landscape. Unlike injectable formulations, orforglipron requires no refrigeration and carries no meal-timing restrictions, features that could substantially broaden global patient access. Its lower manufacturing cost further strengthens its competitive profile against existing GLP-1 receptor agonist therapies.

SemaglutideGLP-1orforglipron
ScienceDaily Sports MedJuly 8, 2026
4 min read
RegulatoryCritical

What's behind the push to make peptide therapies more readily available

NPR examines the growing movement to expand legal access to peptide therapies through compounding pharmacies, which argue they should be permitted to manufacture these compounds to meet surging consumer demand. The therapies, frequently marketed for longevity and wellness benefits, currently occupy a regulatory grey area that leaves patients and providers navigating an uncertain legal landscape. The report highlights ongoing tension between the FDA's oversight authority and compounding pharmacy advocates seeking clearer pathways to patient access.

BPC-157TB-500
NPR HealthJuly 8, 2026
5 min read
IndustryHigh

Hospital Under Investigation; 4,000 Nurses Strike; Fentanyl Makers Pivot to Peptides

A notable development within a broader healthcare news roundup highlights that former fentanyl manufacturers are pivoting their operations toward peptide production, underscoring the rapid commercial growth of the peptide therapy sector. This shift reflects the increasing demand for peptides across wellness, longevity, and therapeutic markets and raises important questions about manufacturing standards and regulatory oversight. The trend signals a significant transformation in pharmaceutical manufacturing priorities as peptides gain mainstream traction.

MedPage TodayJuly 8, 2026
4 min read
IndustryHigh

Biohaven looks to take on Lilly in the muscle-sparing obesity space

Biohaven is entering the competitive obesity therapeutics market with a focus on muscle-sparing approaches, positioning itself against Eli Lilly in a space increasingly defined by GLP-1 and GIP receptor agonist mechanisms. The move signals growing industry recognition that next-generation obesity treatments must address lean mass preservation alongside weight reduction. This development reflects the expanding pipeline of companies seeking differentiated assets beyond first-generation GLP-1 therapies.

GLP-1GIP
Endpoints NewsJuly 8, 2026
4 min read
Clinical TrialsCritical

Record High GLP-1 Use; Intense Interval Exercise; Endometriosis and Androgens

A national Gallup poll reveals that Americans' use of GLP-1 injectable therapies for weight loss has nearly quadrupled since 2024, reaching a record high and signaling a dramatic shift in the obesity treatment landscape. GLP-1 receptor agonists are also gaining attention for their benefits in patients managing type 2 diabetes alongside peripheral artery disease. The data underscore the accelerating mainstream adoption of peptide-based metabolic therapies across multiple clinical indications.

GLP-1SemaglutideTirzepatide
MedPage TodayJuly 7, 2026
5 min read
RegulatoryHigh

STAT+: 'Secret shopper' study probes GLP-1 telehealth sites

A secret shopper investigation into telehealth platforms prescribing GLP-1 medications has surfaced concerns about prescribing standards, patient screening practices, and oversight within the rapidly expanding digital health sector. The study highlights the regulatory and clinical quality challenges that accompany the surge in demand for GLP-1 therapies facilitated through online channels. These findings are likely to draw increased scrutiny from regulators and payers monitoring the telehealth prescribing ecosystem.

GLP-1
STAT NewsJuly 7, 2026
4 min read
Clinical TrialsHigh

Hengrui, Kailera's GLP-1 pill posts encouraging efficacy but high side effect rates in late-stage China trials

Hengrui Pharma and Kailera Therapeutics have reported late-stage trial results for an oral GLP-1 receptor agonist in both obesity and type 2 diabetes indications, showing promising efficacy outcomes alongside notable safety concerns. The elevated side effect rates observed in these China-based trials raise questions about tolerability that developers will need to address before potential global regulatory submissions. The findings contribute to the growing body of evidence shaping the competitive landscape for next-generation oral GLP-1 therapies.

GLP-1
Endpoints NewsJuly 7, 2026
4 min read
RegulatoryHigh

Secret Shopper Study Warns About Online GLP-1 Sellers

A secret shopper study examining 49 online GLP-1 receptor agonist sellers found that two-thirds did not require patients to speak with a clinician prior to receiving a prescription. Only 13 of the tested websites mandated a video visit, raising significant concerns about prescribing standards and patient safety in the telehealth space. The findings underscore ongoing regulatory scrutiny surrounding the direct-to-consumer distribution of GLP-1 therapies.

GLP-1
MedPage TodayJuly 6, 2026
4 min read
RegulatoryCritical

Restrictions could be lifted on peptides loved by wellness influencers

NPR Health reports that Biden-era FDA restrictions that pushed numerous wellness-oriented peptides into a regulatory gray market may be reversed under the current Trump administration. Compounded peptides popular among longevity and performance communities have faced limited availability since being removed from the FDA's bulk substances list in recent years. A policy shift could significantly alter access to these compounds and reshape the compounding pharmacy landscape for peptide therapies.

BPC-157TB-500EpithalonIpamorelinCJC-1295SelankSemax
NPR HealthJuly 6, 2026
5 min read
RegulatoryCritical

Opinion: The smart way to regulate the peptide boom

Former U.S. Surgeon General Jerome Adams has called for a structured, clinician-guided regulatory framework as an alternative to outright bans on popular compounded and wellness peptides. Writing in STAT News, Adams argues that a middle-ground approach would preserve patient access while establishing meaningful safety standards for the growing peptide therapy market. The opinion piece reflects a broader national conversation about how federal regulators should address the rapid proliferation of peptide use outside traditional clinical settings.

BPC-157TB-500GLP-1
STAT NewsJuly 6, 2026
4 min read
RegulatoryHigh

STAT+: Online GLP-1 prescriptions are often fast, easy — and low on clinical oversight

A secret-shopper study published in JAMA and conducted by Yale researchers found that telehealth platforms are frequently dispensing GLP-1 prescriptions without adequate clinical evaluation or oversight. The findings raise serious patient safety concerns regarding the commoditization of GLP-1 therapies through digital health channels. Regulators and clinicians may face increasing pressure to establish stricter prescribing standards for GLP-1 receptor agonists in the telehealth space.

GLP-1
STAT NewsJuly 6, 2026
5 min read
Clinical TrialsHigh

Oral GLP-1 Drug May Simplify Diabetes Treatment

Data presented at the American Diabetes Association annual meeting from the ACHIEVE-5 trial demonstrated that oral orforglipron added to basal insulin produced significant improvements in glycemic control and body weight reduction. The findings position orforglipron as a potential option for patients requiring simplified administration compared to injectable GLP-1 receptor agonists. This development may broaden the therapeutic landscape for oral incretin-based diabetes management.

GLP-1Orforglipron
MedPage TodayJuly 6, 2026
4 min read
RegulatoryHigh

New CDER appointment elevates longtime GLP-1 reviewer

The FDA's Center for Drug Evaluation and Research has appointed Lisa Yanoff, a veteran agency staffer with deep expertise in metabolic drug reviews including GLP-1 therapies, as acting deputy director under CDER chief Michael Davis. The appointment signals continued institutional focus on the rapidly expanding class of incretin-based treatments. Her elevation may have meaningful implications for the pace and direction of GLP-1 and related drug approvals in the near term.

GLP-1
Endpoints NewsJuly 6, 2026
3 min read
LongevityMedium

Fight Aging! Newsletter, July 6th 2026

The July 2026 edition of the Fight Aging! newsletter covers emerging research into age-related biological mechanisms, including the role of NOX4 in muscle adaptation decline and the use of secreted proteins to assess cellular senescence burden from blood samples. These topics are directly relevant to the longevity and peptide therapy fields, as senescence mapping and muscle regeneration pathways intersect with investigational peptide interventions. The newsletter serves as a key resource for researchers and investors tracking the frontier of aging biology and therapeutic development.

Fight AgingJuly 5, 2026
5 min read
RegulatoryCritical

Medicare Is Now Covering Some GLP-1s for Weight-Loss for $50. Here's What to Know

The federal government has begun offering select brand-name GLP-1 receptor agonists for weight loss to eligible Medicare beneficiaries at a capped cost of $50, marking a significant policy shift in access to obesity treatment for older Americans. This development substantially reduces the financial barrier that has historically limited uptake of these medications among Medicare populations. The change is expected to drive increased demand and reshape the landscape for GLP-1 prescribing, compounding, and coverage nationwide.

GLP-1SemaglutideTirzepatide
MedPage TodayJuly 3, 2026
4 min read
RegulatoryCritical

FDA Scientists Raise Peptide Concerns Ahead of Committee Meeting

FDA career scientists have concluded there is insufficient evidence to support the compounding of peptides currently under consideration, placing them at odds with HHS Secretary Robert F. Kennedy Jr.'s recent push to broaden peptide access. The findings are set to influence an upcoming advisory committee meeting that could shape the regulatory future of compounded peptide therapies. The outcome carries significant implications for compounding pharmacies and patients who rely on access to these treatments outside of traditional pharmaceutical approval pathways.

BPC-157TB-500CJC-1295IpamorelinPT-141
MedPage TodayJuly 1, 2026
5 min read
ResearchMedium

The First Year Of GLP-1 Use Comes With This Hard-To-Detect Side Effect

Experts are raising concerns that the first year of GLP-1 receptor agonist use may be associated with nutrient deficiencies, a side effect that is difficult to detect without targeted monitoring. Reduced appetite and food intake driven by these medications may limit patients ability to obtain adequate micronutrients, warranting greater clinical attention to nutritional status. The findings highlight the importance of comprehensive patient management protocols alongside GLP-1 therapy.

GLP-1
MindBodyGreenJuly 1, 2026
3 min read
ResearchHigh

STAT+: More signs that GLP-1s may help with peripheral artery disease

Emerging evidence suggests that GLP-1 receptor agonists may provide therapeutic benefit for patients with peripheral artery disease, a serious vascular condition with limited treatment options. The report adds to a rapidly expanding profile of cardiovascular and vascular indications being associated with GLP-1 class therapies. These developments continue to broaden the clinical relevance of GLP-1 receptor agonists beyond their established metabolic applications.

GLP-1
STAT NewsJuly 1, 2026
3 min read
ResearchHigh

GLP-1s Linked to Systemic Clinical Risk Reduction in Hidradenitis Suppurativa

A large retrospective cohort study has found that patients with hidradenitis suppurativa who used GLP-1 receptor agonists for diabetes or obesity experienced significantly lower rates of cardiovascular events and mortality. The findings extend the known systemic benefits of GLP-1 therapies beyond metabolic disease into the realm of inflammatory dermatological conditions. This research adds to a growing body of evidence supporting the broad cardioprotective and anti-inflammatory properties of GLP-1 receptor agonists.

GLP-1
MedPage TodayJuly 1, 2026
4 min read
LongevityMedium

Study Maps Existing Drugs to the Hallmarks of Aging

A newly published study introduces a network-based methodology for identifying existing drugs with potential longevity-extending properties by detecting signals within protein interaction networks tied to the hallmarks of aging. The approach offers a systematic framework that could accelerate the repurposing of known compounds, potentially including peptide-based therapeutics, toward lifespan extension. Researchers believe this method could meaningfully narrow the gap between current pharmacological knowledge and the development of validated anti-aging interventions.

Lifespan.ioJune 30, 2026
4 min read
RegulatoryCritical

FDA scientists flag concerns with peptides, the trendy molecules RFK Jr. supports

FDA scientists have raised formal concerns regarding the evidence base for peptide therapies, citing insufficient data on efficacy and safety across numerous compounds currently available through compounding pharmacies. An upcoming FDA advisory panel is set to deliberate on whether access to these peptides should be eased, a move supported by Health and Human Services Secretary RFK Jr. but met with skepticism from agency researchers. The proceeding represents a pivotal regulatory moment that could reshape compounding pharmacy access and clinical use of peptide therapies nationwide.

BPC-157TB-500
NPR HealthJune 30, 2026
6 min read
Clinical TrialsHigh

GLP-1s After Surgery; Retatrutide for Pulmonary Hypertension? Vit D for Prediabetes

New U.S. cohort data demonstrate that incretin-based therapies administered following bariatric surgery produce clinically meaningful augmented weight loss in a dose- and timing-dependent fashion, reinforcing the therapeutic value of GLP-1 receptor agonists beyond standalone use. Emerging research also examines retatrutide, a triple agonist targeting GLP-1, GIP, and glucagon receptors, as a potential treatment for pulmonary hypertension, broadening the clinical scope of next-generation incretin therapies. These findings collectively underscore the expanding utility of peptide-based metabolic interventions across multiple disease states.

GLP-1RetatrutideGIP
MedPage TodayJune 30, 2026
5 min read
IndustryMedium

STAT+: Unredacted comments from California hospital lawsuits show stunning admissions and a 'forced' McKinsey collaboration

A Health Care Inc. newsletter from STAT News references GLP-1 usage trends alongside consumer spending data, reflecting the continued integration of GLP-1 receptor agonists into mainstream healthcare economics discussions. The framing of GLP-1 usage in relation to household cost behavior illustrates how broadly adopted these therapies have become across the United States. This consumer-level impact data is increasingly relevant to industry participants tracking the market trajectory of GLP-1 based treatments.

GLP-1
STAT NewsJune 29, 2026
3 min read
RegulatoryMedium

Half of states sue over Medicaid work requirements

A Morning Rounds health briefing from STAT News briefly references the FDA peptide advisory panel, connecting it to a broader news cycle covering major health policy developments. The mention signals that the FDA peptide committee proceedings have reached a level of public and legislative prominence warranting inclusion in mainstream health news summaries. Stakeholders in the peptide therapy community should note the growing policy attention directed at compounding and peptide access issues.

STAT NewsJune 30, 2026
3 min read
IndustryHigh

STAT+: Investors double down on Bain-backed startup

A STAT News briefing references the Trump administration's plan to lower GLP-1 drug prices, a policy development with broad implications for the compounded GLP-1 market and branded manufacturers alike. Pricing pressure from federal policy could reshape competitive dynamics between branded GLP-1 therapies and compounded alternatives. The intersection of executive pricing initiatives and ongoing FDA compounding reviews makes this a notable development for the peptide and metabolic therapy sectors.

GLP-1SemaglutideTirzepatide
STAT NewsJune 30, 2026
3 min read
RegulatoryHigh

STAT+: Pharmalittle: We're reading about Chinese trial sites being probed, RFK Jr. and peptides, and more

A recent Pharmalittle roundup from STAT News highlights coverage of RFK Jr. and his public positions on peptide therapies, drawing attention to the political dimensions surrounding peptide regulation in the United States. The inclusion of peptides alongside high-profile legislative and regulatory discussions underscores the growing mainstream policy interest in this therapeutic category. Industry stakeholders are closely monitoring how political commentary from senior health officials may influence ongoing FDA advisory proceedings.

STAT NewsJune 30, 2026
3 min read
RegulatoryCritical

FDA reviewers oppose allowing seven peptides for compounding

FDA staff reviewers have recommended against adding seven widely used peptides to the bulk drug substances list ahead of a key advisory committee meeting, signaling significant regulatory headwinds for the compounding pharmacy industry. The agency's position could restrict patient access to commonly prescribed peptide therapies if the committee aligns with reviewer recommendations. This development represents one of the most consequential regulatory decisions for the peptide therapy space in recent years.

BPC-157TB-500CJC-1295IpamorelinPT-141SelankEpithalon
Endpoints NewsJune 30, 2026
5 min read
RegulatoryCritical

FDA Panel on Peptides Will Include Experts Who Promote the Unproven Chemicals

The FDA is set to convene a panel reconsidering a list of controversial peptide drugs, and new disclosures reveal that several participating experts hold significant financial ties to the peptide therapy industry. This development raises questions about potential conflicts of interest in the regulatory review process for compounded peptides. The panel's composition and outcomes are expected to have meaningful implications for how unapproved peptide compounds are classified and regulated going forward.

BPC-157TB-500
MedPage TodayJune 29, 2026
5 min read
ResearchMedium

G9a Deficiency Increases Muscle Regeneration

New research identifying G9a deficiency as a driver of enhanced muscle tissue regeneration adds to a rapidly expanding body of work aimed at counteracting muscle loss associated with GLP-1 receptor agonist therapies. The widespread clinical adoption of GLP-1 agents has intensified demand for complementary interventions that preserve or rebuild lean muscle mass lost alongside adipose tissue. This discovery represents a potential mechanistic target for future peptide or small molecule therapies designed to support muscle maintenance in aging and metabolic disease populations.

GLP-1
Fight AgingJune 29, 2026
4 min read
Clinical TrialsHigh

Could Early Tirzepatide Alter the Course of Type 2 Diabetes?

Two-year results from the SUPPRESS-EARLY trial, presented at the American Diabetes Association annual meeting, indicate that initiating tirzepatide early in the course of type 2 diabetes produces substantially higher rates of glycemic benefit compared to delayed treatment. The findings suggest that early intervention with the dual GIP and GLP-1 receptor agonist may meaningfully alter disease progression rather than simply managing symptoms. These results reinforce growing clinical interest in repositioning tirzepatide as a disease-modifying therapy rather than a late-stage intervention.

TirzepatideGLP-1GIP
MedPage TodayJune 29, 2026
4 min read
RegulatoryCritical

STAT+: Longevity, wellness physicians named to panel advising FDA on peptides

The FDA has appointed longevity and wellness physicians to a new advisory panel tasked with evaluating current restrictions on certain peptides. The committee is expected to soon deliberate on whether regulatory constraints on specific peptide compounds should be relaxed, a decision that could have sweeping implications for compounding pharmacies and peptide therapy practitioners. The composition of the panel has drawn scrutiny over potential conflicts of interest among its named advisers.

STAT NewsJune 29, 2026
5 min read
Clinical TrialsHigh

STAT+: Embryo editing advances reignite ethical debates

STAT News reports on Eli Lilly's retatrutide pipeline activity, a triple agonist targeting GLP-1, GIP, and glucagon receptors that has drawn significant attention in the metabolic disease and peptide therapy communities. Retatrutide represents a next-generation advance beyond existing dual agonist therapies, with early clinical data suggesting superior weight loss outcomes. Its continued development underscores the rapid evolution of receptor agonist peptide therapeutics as a dominant force in metabolic medicine.

RetatrutideGLP-1GIP
STAT NewsJune 26, 2026
4 min read
LongevityMedium

Fight Aging! Newsletter, June 29th 2026

The latest Fight Aging! newsletter covers advances in aging biology research, including chromatin accessibility aging clocks assessed across multiple immune cell types and detailed mapping of cellular senescence burden in aged humans. These findings carry direct relevance to the longevity peptide field, where senolytic and senomorphic peptide strategies are being explored as therapeutic interventions. The newsletter provides a broad view of the science underpinning next-generation longevity treatments for researchers and investors in the space.

Fight AgingJune 28, 2026
6 min read
ResearchHigh

Taste, Smell Disturbances Seen in GLP-1 Users

A new analysis of electronic health record data has found that GLP-1 receptor agonist use is associated with an elevated risk of smell and taste disturbances in adults with type 2 diabetes. The findings add to the growing body of post-market safety data surrounding this widely prescribed drug class. Clinicians and patients considering GLP-1 therapy may need to weigh these sensory side effects as part of informed treatment decisions.

GLP-1
MedPage TodayJune 26, 2026
4 min read
Clinical TrialsHigh

What is pulmonary hypertension and why would a new GLP-1 help?

Emerging reports of experimental GLP-1 receptor agonist use in pulmonary hypertension patients have drawn renewed attention to the cardiovascular applications of this drug class. Researchers and clinicians are examining whether GLP-1 based therapies could address the underlying metabolic and vascular dysfunction associated with the condition. The development signals a potential expansion of GLP-1 indications well beyond obesity and type 2 diabetes management.

GLP-1Retatrutide
STAT NewsJune 26, 2026
4 min read
Clinical TrialsMedium

The "Telomere Rivers" Approach Aiming at an Initial Academic Phase 1 Trial

Biotech company Sentcell is advancing its immune rejuvenation technology, based on structured extracellular telomere fragments secreted by CD4+ T cells, toward a first-in-human academic Phase 1 clinical trial. The approach has drawn measured skepticism from researchers due to the unusually large lifespan extension reported in a small mouse study, though sufficient institutional confidence exists to move the program forward. This trial will serve as a critical early test of whether telomere-based immune rejuvenation therapies can translate preclinical findings into human biology.

Fight AgingJune 25, 2026
5 min read
LongevityMedium

An Insurance Industry Viewpoint on the Utility of Aging Clocks

The life insurance industry, given its deep financial stake in mortality prediction, is increasingly engaging with advances in longevity science and biological aging clocks as tools for risk assessment. Industry analysts are evaluating whether emerging therapies targeting the biology of aging represent an existential disruption or a strategic opportunity for insurers. This perspective offers a valuable signal regarding the broader commercial and institutional legitimacy being granted to longevity medicine.

Fight AgingJune 25, 2026
5 min read
RegulatoryHigh

Democrats Press Trump Admin on Special Access to Obesity Drug

Democratic lawmakers are demanding transparency from the Trump administration regarding who received special access to Eli Lilly's investigational obesity drug retatrutide. Senator Maggie Hassan sent a formal letter to HHS Secretary Robert F. Kennedy Jr. seeking disclosure of recipients of the investigational triple hormone receptor agonist. The inquiry raises significant questions about equitable access and regulatory oversight of next-generation GLP-1 class obesity therapeutics.

RetatrutideGLP-1GIP
MedPage TodayJune 25, 2026
4 min read
RegulatoryCritical

Compounder Olympia Pharmaceuticals eyes peptide opportunity

Olympia Pharmaceuticals is positioning itself to capitalize on a forthcoming FDA advisory committee meeting that will consider lifting a ban on several peptides currently marketed for wellness purposes. Compounding pharmacies across the sector have been preparing for this regulatory inflection point, anticipating new opportunities to formulate and distribute previously restricted peptide therapies. The development represents one of the most significant near-term regulatory events for the compounding and peptide therapy industry.

BPC-157TB-500CJC-1295IpamorelinPT-141Epithalon
Endpoints NewsJune 25, 2026
5 min read
Clinical TrialsHigh

Bowel Disease, GLP-1s, and Colon Cancer; Herbs for MASLD? Managing Bile Duct Stones

A retrospective study presented at the American Society of Clinical Oncology found that GLP-1 receptor agonist use in patients with inflammatory bowel disease was associated with a reduced risk of colorectal cancer. The findings add to a growing body of evidence suggesting oncologic benefits of GLP-1 therapies beyond their established metabolic indications. Researchers and clinicians are increasingly focused on understanding the broader protective mechanisms these agents may confer in high-risk gastrointestinal populations.

GLP-1
MedPage TodayJune 25, 2026
4 min read
IndustryHigh

STAT+: U.S. health spending rose sharply in 2025, thanks to GLP-1 use and more care

U.S. healthcare spending surged in 2025, with GLP-1 receptor agonist drugs identified as a primary driver of the increase alongside broader utilization trends. The rapid adoption of GLP-1 therapies such as semaglutide and tirzepatide continues to reshape national healthcare expenditure at a significant scale. This trend underscores the growing economic footprint of peptide-based therapeutics within the broader healthcare system.

GLP-1SemaglutideTirzepatide
STAT NewsJune 24, 2026
4 min read
RegulatoryHigh

RFK Jr.'s Vax Agenda Lives; Filler 'Smuggling' Accusations; Peptide Gray Market

A MedPage Today special report touches on the growing concerns surrounding the peptide gray market, highlighting the regulatory ambiguity that continues to fuel unvetted access to peptide compounds outside established medical channels. The piece underscores ongoing tensions between consumer demand for peptide therapies and the lack of comprehensive federal oversight. Industry observers note that the gray market poses meaningful patient safety risks as well as reputational challenges for legitimate peptide therapy providers.

MedPage TodayJune 24, 2026
5 min read
Clinical TrialsHigh

Are People With Eating Disorders Misusing GLP-1 Drugs?

An ongoing cross-sectional study of over 400 individuals with eating disorders found that 32.1% reported using GLP-1 receptor agonists, with a notable subset engaging in misuse patterns. The findings raise significant clinical and ethical concerns about the intersection of eating disorder pathology and the widespread availability of GLP-1 medications. Clinicians and prescribers are urged to screen for eating disorder histories before initiating GLP-1 therapy.

GLP-1SemaglutideTirzepatide
MedPage TodayJune 24, 2026
4 min read
ResearchHigh

FGF21 Gene Therapy Improves Health in Aged Mice

Researchers have demonstrated that AAV-delivered FGF21 gene therapy produces broad improvements in organ function and healthspan across both aged and geriatric male and female mice. FGF21, a peptide hormone central to the biological response to calorie restriction and low protein intake, has emerged as a compelling target for gerotherapeutic intervention. The findings add meaningful preclinical support for peptide-based and gene therapy strategies aimed at mimicking the protective effects of dietary restriction without behavioral compliance requirements.

FGF21
Fight AgingJune 23, 2026
5 min read
RegulatoryHigh

White House Denies Trump Got Unapproved Obesity Drug

The White House issued a strong denial following reports suggesting President Trump may have received retatrutide, an investigational obesity medication developed by Eli Lilly, through a compassionate use authorization granted by the FDA. The situation draws significant attention to the regulatory pathway for experimental GLP-1 class receptor agonists and the criteria governing single-patient access programs. The incident underscores ongoing public and political scrutiny surrounding next-generation obesity therapeutics currently in clinical development.

RetatrutideGLP-1
MedPage TodayJune 23, 2026
4 min read